Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,078
archived clinical trials in
Major Depression Disorder (MDD)

AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Little Rock, AR
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Los Angeles, CA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Orange, CA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Orange, CA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
San Diego, CA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Santa Ana, CA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Santa Ana, CA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Hartford, CT
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Hartford, CT
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
New Haven, CT
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Boca Raton, FL
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Boca Raton, FL
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Gainsville, FL
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Gainsville, FL
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Hollywood, FL
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Hollywood, FL
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Jacksonville, FL
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Jacksonville, FL
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Atlanta, GA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Roswell, GA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Roswell, GA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Hoffman Estates, IL
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Hoffman Estates, IL
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Joliet, IL
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Joliet, IL
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Overland Park, KA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Overland Park, KA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Lake Charles, LA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Lake Charles, LA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Shreveport, LA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Haverhill, MA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Haverhill, MA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
St. Louis, MO
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Willingboro, NJ
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Willingboro, NJ
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Albuquerque, NM
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Rochester, NY
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
East Stroudsburg, PA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
East Stroudsburg, PA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Philadelphia, PA
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Austin, TX
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated:  7/16/2012
Clinical Research Facility
mi
from
Dallas, TX
AZD6765 Severe Major Depressive Disorder (MDD) IV
A Phase IIb, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Efficacy and Safety Study of Adjunctive AZD6765 in Subjects With Severe Major Depressive Disorder (MDD) and a History of Poor Response to Antidepressants
Status: Enrolling
Updated: 7/16/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Garden Grove, CA
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Denver, CO
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Denver, CO
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Bradenton, FL
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Bradenton, FL
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Atlanta, GA
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Atlanta, GA
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Chicago, IL
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Prairie Village, KA
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Prairie Village, KA
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Baltimore, MD
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Boston, MA
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Boston, MA
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Omaha, NE
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Las Vegas, NV
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Toms River, NJ
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Toms River, NJ
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Brooklyn, NY
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Cincinnati, OH
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Portland, OR
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Lincoln, RI
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Lincoln, RI
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Memphis, TN
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Memphis, TN
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Austin, TX
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Austin, TX
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Salt Lake City, UT
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Seattle, WA
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated:  7/18/2012
Vanda Investigational Site
mi
from
Brown Deer, WI
Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder
MAGELLAN: A Multicenter, Randomized, Double-Masked, Placebo-Controlled, Parallel Study to Investigate the Safety and Efficacy of 20 Mg Tasimelteon Versus Placebo in Adult Subjects With Major Depressive Disorder Followed by a 52-Week Open-Label Extension
Status: Enrolling
Updated: 7/18/2012
Vanda Investigational Site
mi
from
Brown Deer, WI
Click here to add this to my saved trials
Antidepressant Therapy in Treating Bipolar Type II Major Depression
Treatment of Bipolar Type II Major Depression
Status: Enrolling
Updated:  7/26/2012
Depression Research Unit - University of Pennsylvania
mi
from
Philadelphia, PA
Antidepressant Therapy in Treating Bipolar Type II Major Depression
Treatment of Bipolar Type II Major Depression
Status: Enrolling
Updated: 7/26/2012
Depression Research Unit - University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Status: Enrolling
Updated:  7/27/2012
Massachusetts General Hospital- Depression Clinical and Research Program
mi
from
Boston, MA
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Status: Enrolling
Updated: 7/27/2012
Massachusetts General Hospital- Depression Clinical and Research Program
mi
from
Boston, MA
Click here to add this to my saved trials
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Status: Enrolling
Updated:  7/27/2012
Vanderbilt University Medical Center
mi
from
Nashville, TN
Ziprasidone Augmentation of SSRIs for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs
A Three-phase Study Designed to Test the Efficacy, Tolerability and Safety of the Combination of Ziprasidone With Selective Serotonin Reuptake Inhibitors (SSRI) for Patients With Major Depressive Disorder (MDD) That do Not Sufficiently Respond to Treatment With SSRIs.
Status: Enrolling
Updated: 7/27/2012
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials